Contrasting effects of filamin A and B proteins in modulating filovirus entry.
Journal
PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
received:
22
12
2022
accepted:
02
08
2023
revised:
28
08
2023
medline:
29
8
2023
pubmed:
16
8
2023
entrez:
16
8
2023
Statut:
epublish
Résumé
Ebola (EBOV) and Marburg viruses (MARV) cause severe hemorrhagic fever associated with high mortality rates in humans. A better understanding of filovirus-host interactions that regulate the EBOV and MARV lifecycles can provide biological and mechanistic insight critical for therapeutic development. EBOV glycoprotein (eGP) and MARV glycoprotein (mGP) mediate entry into host cells primarily by actin-dependent macropinocytosis. Here, we identified actin-binding cytoskeletal crosslinking proteins filamin A (FLNa) and B (FLNb) as important regulators of both EBOV and MARV entry. We found that entry of pseudotype psVSV-RFP-eGP, infectious recombinant rVSV-eGP-mCherry, and live authentic EBOV and MARV was inhibited in filamin A knockdown (FLNaKD) cells, but was surprisingly enhanced in filamin B knockdown (FLNbKD) cells. Mechanistically, our findings suggest that differential regulation of macropinocytosis by FLNa and FLNb likely contributes to their specific effects on EBOV and MARV entry. This study is the first to identify the filamin family of proteins as regulators of EBOV and MARV entry. These findings may provide insight into the development of new countermeasures to prevent EBOV and MARV infections.
Identifiants
pubmed: 37585478
doi: 10.1371/journal.ppat.1011595
pii: PPATHOGENS-D-22-02224
pmc: PMC10461817
doi:
Substances chimiques
Filamins
0
Actins
0
Glycoproteins
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1011595Informations de copyright
Copyright: © 2023 Shepley-McTaggart et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Infect Dis. 2018 Nov 22;218(suppl_5):S346-S354
pubmed: 29947774
Int J Mol Sci. 2016 Jan 08;17(1):
pubmed: 26760998
Nat Protoc. 2014 Jan;9(1):182-92
pubmed: 24385148
Proc Natl Acad Sci U S A. 2013 Aug 27;110(35):14402-7
pubmed: 23940347
J Gen Virol. 1987 Feb;68 ( Pt 2):387-99
pubmed: 3029282
Antiviral Res. 2018 Jan;149:154-163
pubmed: 29175127
Proc Natl Acad Sci U S A. 2009 May 12;106(19):8003-8
pubmed: 19416892
Future Virol. 2009;4(6):621-635
pubmed: 20198110
MethodsX. 2014 Jun 02;1:36-41
pubmed: 26150932
Hum Mol Genet. 2002 Nov 1;11(23):2845-54
pubmed: 12393796
J Biol Chem. 2011 Aug 12;286(32):28498-510
pubmed: 21705339
PLoS One. 2013 Nov 05;8(11):e79877
pubmed: 24224016
Hum Mol Genet. 2017 Apr 1;26(7):1294-1304
pubmed: 28175289
Nature. 2011 Aug 24;477(7364):340-3
pubmed: 21866103
J Biol Chem. 2010 Apr 2;285(14):10748-60
pubmed: 20110358
Viruses. 2012 Feb;4(2):258-75
pubmed: 22470835
Nat Cell Biol. 2004 Nov;6(11):1034-8
pubmed: 15516996
FASEB J. 2021 May;35(5):e21560
pubmed: 33860543
Nat Commun. 2021 Nov 12;12(1):6577
pubmed: 34772942
Virology. 2016 Jan 15;488:202-15
pubmed: 26655238
PLoS Pathog. 2010 Sep 23;6(9):e1001121
pubmed: 20886108
Mol Biol Cell. 2008 Dec;19(12):5116-30
pubmed: 18815275
mBio. 2014 Oct 28;5(6):e02012
pubmed: 25352621
Future Virol. 2010;5(1):85-96
pubmed: 23516023
J Virol. 2015 Jun;89(12):6481-93
pubmed: 25855742
J Viral Hepat. 2011 Oct;18(10):e568-77
pubmed: 21914078
PLoS Negl Trop Dis. 2019 Jun 26;13(6):e0006983
pubmed: 31242184
J Infect Dis. 2015 Oct 1;212 Suppl 2:S247-57
pubmed: 25877552
Virology. 2008 Mar 30;373(1):189-201
pubmed: 18083206
J Biol Chem. 2016 Feb 19;291(8):4236-46
pubmed: 26742839
Nat Med. 2004 Dec;10(12 Suppl):S110-21
pubmed: 15577929
Adv Exp Med Biol. 2022;1366:155-170
pubmed: 35412140
Viruses. 2019 Mar 19;11(3):
pubmed: 30893774
Nat Cell Biol. 2001 Dec;3(12):1060-8
pubmed: 11781567
Nat Cell Biol. 2007 Jul;9(7):838-46
pubmed: 17572668
Virology. 2000 Dec 5;278(1):20-6
pubmed: 11112476
Antimicrob Agents Chemother. 2021 Jun 17;65(7):e0008621
pubmed: 33846137
Biochem J. 2004 Jan 1;377(Pt 1):159-69
pubmed: 14505488
PLoS One. 2009 Nov 13;4(11):e7830
pubmed: 19915675
J Virol. 2006 Oct;80(20):10109-16
pubmed: 17005688
Cell Adh Migr. 2011 Mar-Apr;5(2):160-9
pubmed: 21169733
Nat Rev Immunol. 2003 Aug;3(8):677-85
pubmed: 12974482
Infect Dis Clin North Am. 2019 Dec;33(4):953-976
pubmed: 31668200
Vet Microbiol. 2016;182:102-7
pubmed: 26711035
Lancet. 2019 Mar 2;393(10174):936-948
pubmed: 30777297
Virology. 2007 Feb 5;358(1):79-88
pubmed: 16989883
Nat Commun. 2020 Feb 28;11(1):1121
pubmed: 32111826
J Cell Sci. 2012 Aug 15;125(Pt 16):3858-69
pubmed: 22595522
PLoS Pathog. 2010 Sep 16;6(9):e1001110
pubmed: 20862315
J Pathol. 2015 Jan;235(2):153-74
pubmed: 25297522
EMBO Rep. 2009 Apr;10(4):374-80
pubmed: 19270716
EMBO Rep. 2009 Apr;10(4):349-51
pubmed: 19305389
PLoS Pathog. 2023 Jan 18;19(1):e1011077
pubmed: 36652443
J Infect Dis. 2011 Nov;204 Suppl 3:S957-67
pubmed: 21987776